{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:49:06Z","timestamp":1793364546787,"version":"4.5.0"},"reference-count":207,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1038\/s41585-024-00914-7","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T07:33:17Z","timestamp":1722583997000},"page":"75-91","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Molecular biomarkers of progression in non-muscle-invasive bladder cancer \u2014 beyond conventional risk stratification"],"prefix":"10.1038","volume":"22","author":[{"given":"Mitchell","family":"Olislagers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6853-5982","authenticated-orcid":false,"given":"Florus C.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera C.","family":"Rutten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5127-0436","authenticated-orcid":false,"given":"Joost L.","family":"Boormans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokameh","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4002-9006","authenticated-orcid":false,"given":"Tahlita C. M.","family":"Zuiverloon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,2]]},"reference":[{"key":"914_CR1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al.\u00a0Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"914_CR2","first-page":"15","volume":"8","author":"K Saginala","year":"2020","unstructured":"Saginala, K. et al. Epidemiology of bladder cancer. Med. Sci. 8, 15 (2020).","journal-title":"Med. Sci."},{"key":"914_CR3","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester, R. J. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49, 466\u2013475; discussion 475\u2013477 (2006).","journal-title":"Eur. Urol."},{"key":"914_CR4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk, M. et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur. Urol. 81, 75\u201394 (2022).","journal-title":"Eur. Urol."},{"key":"914_CR5","volume":"8","author":"P Ge","year":"2018","unstructured":"Ge, P. et al. Oncological outcome of primary and secondary muscle-invasive bladder cancer: a systematic review and meta-analysis. Sci. Rep. 8, 7543 (2018).","journal-title":"Sci. Rep."},{"key":"914_CR6","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.euros.2022.05.001","volume":"41","author":"D D\u2019Andrea","year":"2022","unstructured":"D\u2019Andrea, D. et al. The impact of primary versus secondary muscle-invasive bladder cancer at diagnosis on the response to neoadjuvant chemotherapy. Eur. Urol. Open. Sci. 41, 74\u201380 (2022).","journal-title":"Eur. Urol. Open. Sci."},{"key":"914_CR7","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.3390\/cancers13102496","volume":"13","author":"M Pones","year":"2021","unstructured":"Pones, M. et al. Differential prognosis and response of denovo vs. secondary muscle-invasive bladder cancer: an updated systematic review and meta-analysis. Cancers 13, 2496 (2021).","journal-title":"Cancers"},{"key":"914_CR8","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00345-018-2550-x","volume":"37","author":"M Mossanen","year":"2019","unstructured":"Mossanen, M. et al. Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. World J. Urol. 37, 2059\u20132065 (2019).","journal-title":"World J. Urol."},{"key":"914_CR9","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernandez-Gomez","year":"2009","unstructured":"Fernandez-Gomez, J. et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J. Urol. 182, 2195\u20132203 (2009).","journal-title":"J. Urol."},{"key":"914_CR10","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"SS Chang","year":"2016","unstructured":"Chang, S. S. et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J. Urol. 196, 1021\u20131029 (2016).","journal-title":"J. Urol."},{"key":"914_CR11","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.eururo.2017.04.015","volume":"72","author":"V Soukup","year":"2017","unstructured":"Soukup, V. et al. Prognostic performance and reproducibility of the 1973 and 2004\/2016 World Health Organization grading classification systems in non-muscle-invasive bladder cancer: a European Association of Urology non-muscle invasive bladder cancer guidelines panel systematic review. Eur. Urol. 72, 801\u2013813 (2017).","journal-title":"Eur. Urol."},{"key":"914_CR12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","volume":"69","author":"S Cambier","year":"2016","unstructured":"Cambier, S. et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance bacillus Calmette-Guerin. Eur. Urol. 69, 60\u201369 (2016).","journal-title":"Eur. Urol."},{"key":"914_CR13","doi-asserted-by":"crossref","first-page":"8.e17","DOI":"10.1016\/j.urolonc.2017.08.027","volume":"36","author":"M Rieken","year":"2018","unstructured":"Rieken, M. et al. Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer. Urol. Oncol. 36, 8.e17\u20138.e24 (2018).","journal-title":"Urol. Oncol."},{"key":"914_CR14","doi-asserted-by":"crossref","first-page":"491.e11","DOI":"10.1016\/j.urolonc.2022.06.008","volume":"40","author":"W Krajewski","year":"2022","unstructured":"Krajewski, W. et al. Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer. Urol. Oncol. 40, 491.e11\u2013491.e19 (2022).","journal-title":"Urol. Oncol."},{"key":"914_CR15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.euo.2021.11.006","volume":"5","author":"N Lobo","year":"2022","unstructured":"Lobo, N. et al. Updated European Association of Urology (EAU) prognostic factor risk groups overestimate the risk of progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin. Eur. Urol. Oncol. 5, 84\u201391 (2022).","journal-title":"Eur. Urol. Oncol."},{"key":"914_CR16","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3233\/BLC-220055","volume":"8","author":"F Guerrero-Ramos","year":"2022","unstructured":"Guerrero-Ramos, F. et al. Predicting recurrence and progression in patients with non-muscle-invasive bladder cancer: systematic review on the performance of risk stratification models. Bladder Cancer 8, 339\u2013357 (2022).","journal-title":"Bladder Cancer"},{"key":"914_CR17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.euf.2018.11.005","volume":"6","author":"V Soukup","year":"2020","unstructured":"Soukup, V. et al. Risk stratification tools and prognostic models in non-muscle-invasive bladder cancer: a critical assessment from the European Association of Urology non-muscle-invasive bladder cancer guidelines panel. Eur. Urol. Focus. 6, 479\u2013489 (2020).","journal-title":"Eur. Urol. Focus."},{"key":"914_CR18","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cam4.3007","volume":"9","author":"M Jobczyk","year":"2020","unstructured":"Jobczyk, M., Stawiski, K., Fendler, W. & Rozanski, W. Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): a cohort analysis. Cancer Med. 9, 4014\u20134025 (2020).","journal-title":"Cancer Med."},{"key":"914_CR19","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/jnci\/84.16.1251","volume":"84","author":"C Cordon-Cardo","year":"1992","unstructured":"Cordon-Cardo, C. et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J. Natl Cancer Inst. 84, 1251\u20131256 (1992).","journal-title":"J. Natl Cancer Inst."},{"key":"914_CR20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/jnci\/85.1.53","volume":"85","author":"AS Sarkis","year":"1993","unstructured":"Sarkis, A. S. et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J. Natl Cancer Inst. 85, 53\u201359 (1993).","journal-title":"J. Natl Cancer Inst."},{"key":"914_CR21","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ctrv.2017.10.004","volume":"61","author":"D Casadevall","year":"2017","unstructured":"Casadevall, D., Kilian, A. Y. & Bellmunt, J. The prognostic role of epigenetic dysregulation in bladder cancer: a systematic review. Cancer Treat. Rev. 61, 82\u201393 (2017).","journal-title":"Cancer Treat. Rev."},{"key":"914_CR22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2016.01.007","volume":"70","author":"K Birkenkamp-Demtroder","year":"2016","unstructured":"Birkenkamp-Demtroder, K. et al. Genomic alterations in liquid biopsies from patients with bladder cancer. Eur. Urol. 70, 75\u201382 (2016).","journal-title":"Eur. Urol."},{"key":"914_CR23","doi-asserted-by":"crossref","first-page":"947446","DOI":"10.3389\/fonc.2022.947446","volume":"12","author":"C De Carlo","year":"2022","unstructured":"De Carlo, C., Valeri, M., Corbitt, D. N., Cieri, M. & Colombo, P. Non-muscle invasive bladder cancer biomarkers beyond morphology. Front. Oncol. 12, 947446 (2022).","journal-title":"Front. Oncol."},{"key":"914_CR24","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/jnci\/93.14.1054","volume":"93","author":"MS Pepe","year":"2001","unstructured":"Pepe, M. S. et al. Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst. 93, 1054\u20131061 (2001).","journal-title":"J. Natl Cancer Inst."},{"key":"914_CR25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.tcb.2021.07.001","volume":"32","author":"J Liu","year":"2022","unstructured":"Liu, J., Peng, Y. & Wei, W. Cell cycle on the crossroad of tumorigenesis and cancer therapy. Trends Cell Biol. 32, 30\u201344 (2022).","journal-title":"Trends Cell Biol."},{"key":"914_CR26","doi-asserted-by":"crossref","first-page":"100472","DOI":"10.1016\/j.xcrm.2021.100472","volume":"2","author":"CD Hurst","year":"2021","unstructured":"Hurst, C. D. et al. Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight. Cell Rep. Med. 2, 100472 (2021).","journal-title":"Cell Rep. Med."},{"key":"914_CR27","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00345-007-0197-0","volume":"25","author":"AP Mitra","year":"2007","unstructured":"Mitra, A. P., Birkhahn, M. & Cote, R. J. p53 and retinoblastoma pathways in bladder cancer. World J. Urol. 25, 563\u2013571 (2007).","journal-title":"World J. Urol."},{"key":"914_CR28","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1002\/ijc.32737","volume":"146","author":"G Sjodahl","year":"2020","unstructured":"Sjodahl, G. et al. Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma. Int. J. Cancer 146, 2636\u20132647 (2020).","journal-title":"Int. J. Cancer"},{"key":"914_CR29","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/1878-0261.12473","volume":"13","author":"V Gatti","year":"2019","unstructured":"Gatti, V., Fierro, C., Annicchiarico-Petruzzelli, M., Melino, G. & Peschiaroli, A. DeltaNp63 in squamous cell carcinoma: defining the oncogenic routes affecting epigenetic landscape and tumour microenvironment. Mol. Oncol. 13, 981\u20131001 (2019).","journal-title":"Mol. Oncol."},{"key":"914_CR30","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi, W. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25, 152\u2013165 (2014).","journal-title":"Cancer Cell"},{"key":"914_CR31","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1007\/s00432-019-03028-5","volume":"145","author":"MA Papadimitriou","year":"2019","unstructured":"Papadimitriou, M. A. et al. DeltaNp63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression. J. Cancer Res. Clin. Oncol. 145, 3075\u20133087 (2019).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"914_CR32","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0002-9440(10)64396-9","volume":"161","author":"MJ Urist","year":"2002","unstructured":"Urist, M. J. et al. Loss of p63 expression is associated with tumor progression in bladder cancer. Am. J. Pathol. 161, 1199\u20131206 (2002).","journal-title":"Am. J. Pathol."},{"key":"914_CR33","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.juro.2014.10.098","volume":"193","author":"JM Gaya","year":"2015","unstructured":"Gaya, J. M. et al. \u0394Np63 expression is a protective factor of progression in clinical high grade T1 bladder cancer. J. Urol. 193, 1144\u20131150 (2015).","journal-title":"J. Urol."},{"key":"914_CR34","volume":"8","author":"FM Khan","year":"2017","unstructured":"Khan, F. M. et al. Unraveling a tumor type-specific regulatory core underlying E2F1-mediated epithelial-mesenchymal transition to predict receptor protein signatures. Nat. Commun. 8, 198 (2017).","journal-title":"Nat. Commun."},{"key":"914_CR35","doi-asserted-by":"crossref","first-page":"9025","DOI":"10.3390\/ijms21239025","volume":"21","author":"JY Mun","year":"2020","unstructured":"Mun, J. Y. et al. E2F1 promotes progression of bladder cancer by modulating rad54l involved in homologous recombination repair. Int. J. Mol. Sci. 21, 9025 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"914_CR36","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.eururo.2020.06.048","volume":"78","author":"AG Robertson","year":"2020","unstructured":"Robertson, A. G. et al. Identification of differential tumor subtypes of T1 bladder cancer. Eur. Urol. 78, 533\u2013537 (2020).","journal-title":"Eur. Urol."},{"key":"914_CR37","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2009.25.0977","volume":"28","author":"JS Lee","year":"2010","unstructured":"Lee, J. S. et al. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J. Clin. Oncol. 28, 2660\u20132667 (2010).","journal-title":"J. Clin. Oncol."},{"key":"914_CR38","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ebiom.2019.10.058","volume":"50","author":"B-N Song","year":"2019","unstructured":"Song, B.-N. et al. Identification of an immunotherapy-responsive molecular subtype of bladder cancer. eBioMedicine 50, 238\u2013245 (2019).","journal-title":"eBioMedicine"},{"key":"914_CR39","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3390\/ijms22031450","volume":"22","author":"SK Kim","year":"2021","unstructured":"Kim, S. K. et al. A molecular signature determines the prognostic and therapeutic subtype of non-muscle-invasive bladder cancer responsive to intravesical bacillus Calmette-Guerin therapy. Int. J. Mol. Sci. 22, 1450 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"914_CR40","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/sj.onc.1207274","volume":"23","author":"A Feber","year":"2004","unstructured":"Feber, A. et al. Amplification and overexpression of E2F3 in human bladder cancer. Oncogene 23, 1627\u20131630 (2004).","journal-title":"Oncogene"},{"key":"914_CR41","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1038\/sj.onc.1207749","volume":"23","author":"M Oeggerli","year":"2004","unstructured":"Oeggerli, M. et al. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene 23, 5616\u20135623 (2004).","journal-title":"Oncogene"},{"key":"914_CR42","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1038\/sj.onc.1210934","volume":"27","author":"CD Hurst","year":"2008","unstructured":"Hurst, C. D., Tomlinson, D. C., Williams, S. V., Platt, F. M. & Knowles, M. A. Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification. Oncogene 27, 2716\u20132727 (2008).","journal-title":"Oncogene"},{"key":"914_CR43","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1158\/1541-7786.MCR-15-0120","volume":"13","author":"C Cheng","year":"2015","unstructured":"Cheng, C., Varn, F. S. & Marsit, C. J. E2F4 program is predictive of progression and intravesical immunotherapy efficacy in bladder cancer. Mol. Cancer Res. 13, 1316\u20131324 (2015).","journal-title":"Mol. Cancer Res."},{"key":"914_CR44","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-22465-w","volume":"12","author":"SV Lindskrog","year":"2021","unstructured":"Lindskrog, S. V. et al. An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat. Commun. 12, 2301 (2021).","journal-title":"Nat. Commun."},{"key":"914_CR45","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1158\/1078-0432.CCR-05-1059","volume":"12","author":"N Ramesh","year":"2006","unstructured":"Ramesh, N. et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor-armed oncolytic adenovirus for the treatment of bladder cancer. Clin. Cancer Res. 12, 305\u2013313 (2006).","journal-title":"Clin. Cancer Res."},{"key":"914_CR46","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","volume":"36","author":"VT Packiam","year":"2018","unstructured":"Packiam, V. T. et al. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results. Urol. Oncol. 36, 440\u2013447 (2018).","journal-title":"Urol. Oncol."},{"key":"914_CR47","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04452591 (2024)."},{"key":"914_CR48","doi-asserted-by":"crossref","first-page":"774845","DOI":"10.3389\/fcell.2021.774845","volume":"9","author":"R Fagundes","year":"2021","unstructured":"Fagundes, R. & Teixeira, L. K. Cyclin E\/CDK2: DNA replication, replication stress and genomic instability. Front. Cell Dev. Biol. 9, 774845 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"914_CR49","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.7150\/jca.24179","volume":"9","author":"H Zhao","year":"2018","unstructured":"Zhao, H. et al. Prognostic values of CCNE1 amplification and overexpression in cancer patients: a systematic review and meta-analysis. J. Cancer 9, 2397\u20132407 (2018).","journal-title":"J. Cancer"},{"key":"914_CR50","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1158\/0008-5472.CAN-20-0977","volume":"80","author":"J Bellmunt","year":"2020","unstructured":"Bellmunt, J. et al. Genomic predictors of good outcome, recurrence, or progression in high-grade T1 non-muscle-invasive bladder cancer. Cancer Res. 80, 4476\u20134486 (2020).","journal-title":"Cancer Res."},{"key":"914_CR51","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.euo.2021.11.002","volume":"5","author":"JVW Bacon","year":"2022","unstructured":"Bacon, J. V. W. et al. Somatic features of response and relapse in non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin immunotherapy. Eur. Urol. Oncol. 5, 677\u2013686 (2022).","journal-title":"Eur. Urol. Oncol."},{"key":"914_CR52","volume":"49","author":"BN Song","year":"2017","unstructured":"Song, B. N., Kim, S. K. & Chu, I. S. Bioinformatic identification of prognostic signature defined by copy number alteration and expression of CCNE1 in non-muscle invasive bladder cancer. Exp. Mol. Med. 49, e282 (2017).","journal-title":"Exp. Mol. Med."},{"key":"914_CR53","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-73642-8","volume":"10","author":"C Le Goux","year":"2020","unstructured":"Le Goux, C. et al. Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer. Sci. Rep. 10, 16641 (2020).","journal-title":"Sci. Rep."},{"key":"914_CR54","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/S0959-8049(22)01010-3","volume":"174","author":"S Wee","year":"2022","unstructured":"Wee, S. et al. Discovery of INCB123667, a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor for the treatment of cyclin E dysregulated cancers. Eur. J. Cancer 174, S79 (2022).","journal-title":"Eur. J. Cancer"},{"key":"914_CR55","doi-asserted-by":"crossref","first-page":"e17546","DOI":"10.1200\/JCO.2023.41.16_suppl.e17546","volume":"41","author":"Y Wang","year":"2023","unstructured":"Wang, Y. Phase 1\/2 study of ARTS-021, a potent, oral administrated, selective CDK2 inhibitor, in advanced or metastatic solid tumors. J. Clin. Oncol. 41, e17546\u2013e17546 (2023).","journal-title":"J. Clin. Oncol."},{"key":"914_CR56","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1128\/MCB.00412-12","volume":"32","author":"H Beck","year":"2012","unstructured":"Beck, H. et al. Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption. Mol. Cell Biol. 32, 4226\u20134236 (2012).","journal-title":"Mol. Cell Biol."},{"key":"914_CR57","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1158\/2159-8290.CD-11-0320","volume":"2","author":"M Aarts","year":"2012","unstructured":"Aarts, M. et al. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov. 2, 524\u2013539 (2012).","journal-title":"Cancer Discov."},{"key":"914_CR58","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ccr.2010.08.011","volume":"18","author":"SE Mir","year":"2010","unstructured":"Mir, S. E. et al. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell 18, 244\u2013257 (2010).","journal-title":"Cancer Cell"},{"key":"914_CR59","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1111\/cas.15051","volume":"112","author":"K Murakami","year":"2021","unstructured":"Murakami, K. et al. Antitumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer. Cancer Sci. 112, 3669\u20133681 (2021).","journal-title":"Cancer Sci."},{"key":"914_CR60","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1200\/JCO.22.00830","volume":"41","author":"S Fu","year":"2023","unstructured":"Fu, S. et al. Multicenter phase II trial of the WEE1 inhibitor adavosertib in refractory solid tumors harboring CCNE1 amplification. J. Clin. Oncol. 41, 1725\u20131734 (2023).","journal-title":"J. Clin. Oncol."},{"key":"914_CR61","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","volume":"22","author":"S Goel","year":"2022","unstructured":"Goel, S., Bergholz, J. S. & Zhao, J. J. Targeting CDK4 and CDK6 in cancer. Nat. Rev. Cancer 22, 356\u2013372 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"914_CR62","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ebiom.2016.04.017","volume":"8","author":"R Zhao","year":"2016","unstructured":"Zhao, R., Choi, B. Y., Lee, M. H., Bode, A. M. & Dong, Z. Implications of genetic and epigenetic alterations of CDKN2A (p16INK4a) in cancer. EBioMedicine 8, 30\u201339 (2016).","journal-title":"EBioMedicine"},{"key":"914_CR63","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1038\/bjc.1998.365","volume":"77","author":"JM Bartlett","year":"1998","unstructured":"Bartlett, J. M. et al. Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder? Br. J. Cancer 77, 2193\u20132198 (1998).","journal-title":"Br. J. Cancer"},{"key":"914_CR64","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0165-4608(01)00618-5","volume":"134","author":"M Tsukamoto","year":"2002","unstructured":"Tsukamoto, M. et al. Numerical aberrations of chromosome 9 in bladder cancer. A possible prognostic marker for early tumor recurrence. Cancer Genet. Cytogenet. 134, 41\u201345 (2002).","journal-title":"Cancer Genet. Cytogenet."},{"key":"914_CR65","doi-asserted-by":"crossref","first-page":"75176","DOI":"10.18632\/oncotarget.12661","volume":"7","author":"JJ Meeks","year":"2016","unstructured":"Meeks, J. J. et al. Genomic characterization of high-risk non-muscle invasive bladder cancer. Oncotarget 7, 75176\u201375184 (2016).","journal-title":"Oncotarget"},{"key":"914_CR66","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/S0022-5347(05)68064-0","volume":"162","author":"I Jung","year":"1999","unstructured":"Jung, I. et al. Chromosome 9 monosomy by fluorescence in situ hybridization of bladder irrigation specimens is predictive of tumor recurrence. J. Urol. 162, 1900\u20131903 (1999).","journal-title":"J. Urol."},{"key":"914_CR67","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/path.4017","volume":"227","author":"S Rebouissou","year":"2012","unstructured":"Rebouissou, S. et al. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma. J. Pathol. 227, 315\u2013324 (2012).","journal-title":"J. Pathol."},{"key":"914_CR68","first-page":"498","volume":"1","author":"G Ploussard","year":"2011","unstructured":"Ploussard, G. et al. The prognostic value of FGFR3 mutational status for disease recurrence and progression depends on allelic losses at 9p22. Am. J. Cancer Res. 1, 498\u2013507 (2011).","journal-title":"Am. J. Cancer Res."},{"key":"914_CR69","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.clgc.2018.01.009","volume":"16","author":"J Breyer","year":"2018","unstructured":"Breyer, J. et al. High CDKN2A\/p16 and low FGFR3 expression predict progressive potential of stage pT1 urothelial bladder carcinoma. Clin. Genitourin. Cancer 16, 248\u2013256.e2 (2018).","journal-title":"Clin. Genitourin. Cancer"},{"key":"914_CR70","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.2147\/CMAR.S318893","volume":"13","author":"D Sikic","year":"2021","unstructured":"Sikic, D. et al. The prognostic value of FGFR3 expression in patients with T1 non-muscle invasive bladder cancer. Cancer Manag. Res. 13, 6567\u20136578 (2021).","journal-title":"Cancer Manag. Res."},{"key":"914_CR71","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1158\/1078-0432.CCR-18-0685","volume":"25","author":"C Rubio","year":"2019","unstructured":"Rubio, C. et al. CDK4\/6 inhibitor as a novel therapeutic approach for advanced bladder cancer independently of RB1 status. Clin. Cancer Res. 25, 390\u2013402 (2019).","journal-title":"Clin. Cancer Res."},{"key":"914_CR72","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03837821 (2024)."},{"key":"914_CR73","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04887831 (2024)."},{"key":"914_CR74","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/ng.2800","volume":"45","author":"DA Solomon","year":"2013","unstructured":"Solomon, D. A. et al. Frequent truncating mutations of STAG2 in bladder cancer. Nat. Genet. 45, 1428\u20131430 (2013).","journal-title":"Nat. Genet."},{"key":"914_CR75","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1038\/ng.2799","volume":"45","author":"C Balbas-Martinez","year":"2013","unstructured":"Balbas-Martinez, C. et al. Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat. Genet. 45, 1464\u20131469 (2013).","journal-title":"Nat. Genet."},{"key":"914_CR76","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1093\/hmg\/ddt589","volume":"23","author":"CF Taylor","year":"2014","unstructured":"Taylor, C. F., Platt, F. M., Hurst, C. D., Thygesen, H. H. & Knowles, M. A. Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes. Hum. Mol. Genet. 23, 1964\u20131974 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"914_CR77","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","volume":"72","author":"EJ Pietzak","year":"2017","unstructured":"Pietzak, E. J. et al. Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets. Eur. Urol. 72, 952\u2013959 (2017).","journal-title":"Eur. Urol."},{"key":"914_CR78","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-020-01731-9","volume":"21","author":"Y Shao","year":"2021","unstructured":"Shao, Y. et al. Prognostic factors of non-muscle invasive bladder cancer: a study based on next-generation sequencing. Cancer Cell Int. 21, 23 (2021).","journal-title":"Cancer Cell Int."},{"key":"914_CR79","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.euros.2022.02.004","volume":"38","author":"NS Gordon","year":"2022","unstructured":"Gordon, N. S. et al. STAG2 protein expression in non-muscle-invasive bladder cancer: associations with sex, genomic and transcriptomic changes, and clinical outcomes. Eur. Urol. Open. Sci. 38, 88\u201395 (2022).","journal-title":"Eur. Urol. Open. Sci."},{"key":"914_CR80","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.urolonc.2021.02.007","volume":"39","author":"A Taber","year":"2021","unstructured":"Taber, A. et al. STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer. Urol. Oncol. 39, 438.e1\u2013438.e9 (2021).","journal-title":"Urol. Oncol."},{"key":"914_CR81","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1158\/1078-0432.CCR-17-3244","volume":"24","author":"A Lelo","year":"2018","unstructured":"Lelo, A. et al. STAG2 is a biomarker for prediction of recurrence and progression in papillary non-muscle-invasive bladder cancer. Clin. Cancer Res. 24, 4145\u20134153 (2018).","journal-title":"Clin. Cancer Res."},{"key":"914_CR82","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00432-018-2694-5","volume":"144","author":"S Rinaldetti","year":"2018","unstructured":"Rinaldetti, S. et al. FOXM1 predicts disease progression in non-muscle invasive bladder cancer. J. Cancer Res. Clin. Oncol. 144, 1701\u20131709 (2018).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"914_CR83","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bju.14525","volume":"123","author":"J Breyer","year":"2019","unstructured":"Breyer, J. et al. FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer. BJU Int. 123, 187\u2013196 (2019).","journal-title":"BJU Int."},{"key":"914_CR84","volume":"7","author":"J Shi","year":"2019","unstructured":"Shi, J., Zhang, P., Liu, L., Min, X. & Xiao, Y. Weighted gene coexpression network analysis identifies a new biomarker of CENPF for prediction disease prognosis and progression in nonmuscle invasive bladder cancer. Mol. Genet. Genom. Med. 7, e982 (2019).","journal-title":"Mol. Genet. Genom. Med."},{"key":"914_CR85","volume":"7","author":"SC Lin","year":"2016","unstructured":"Lin, S. C. et al. Dysregulation of miRNAs-COUP-TFII-FOXM1-CENPF axis contributes to the metastasis of prostate cancer. Nat. Commun. 7, 11418 (2016).","journal-title":"Nat. Commun."},{"key":"914_CR86","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ccr.2014.03.017","volume":"25","author":"A Aytes","year":"2014","unstructured":"Aytes, A. et al. Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell 25, 638\u2013651 (2014).","journal-title":"Cancer Cell"},{"key":"914_CR87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2023.03.007","volume":"92","author":"MA Khan","year":"2023","unstructured":"Khan, M. A., Khan, P., Ahmad, A., Fatima, M. & Nasser, M. W. FOXM1: a small fox that makes more tracks for cancer progression and metastasis. Semin. Cancer Biol. 92, 1\u201315 (2023).","journal-title":"Semin. Cancer Biol."},{"key":"914_CR88","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.molcel.2012.03.005","volume":"46","author":"AA Jeyaprakash","year":"2012","unstructured":"Jeyaprakash, A. A. et al. Structural and functional organization of the Ska complex, a key component of the kinetochore-microtubule interface. Mol. Cell 46, 274\u2013286 (2012).","journal-title":"Mol. Cell"},{"key":"914_CR89","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1038\/emboj.2009.96","volume":"28","author":"TN Gaitanos","year":"2009","unstructured":"Gaitanos, T. N. et al. Stable kinetochore-microtubule interactions depend on the Ska complex and its new component Ska3\/C13Orf3. EMBO J. 28, 1442\u20131452 (2009).","journal-title":"EMBO J."},{"key":"914_CR90","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/path.4374","volume":"234","author":"J Li","year":"2014","unstructured":"Li, J. et al. SKA1 over-expression promotes centriole over-duplication, centrosome amplification and prostate tumourigenesis. J. Pathol. 234, 178\u2013189 (2014).","journal-title":"J. Pathol."},{"key":"914_CR91","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3233\/CBM-181202","volume":"22","author":"S Jiang","year":"2018","unstructured":"Jiang, S. et al. High expression of spindle and kinetochore-associated protein 1 predicts early recurrence and progression of non-muscle invasive bladder cancer. Cancer Biomark. 22, 543\u2013549 (2018).","journal-title":"Cancer Biomark."},{"key":"914_CR92","doi-asserted-by":"crossref","first-page":"1012999","DOI":"10.3389\/fimmu.2023.1012999","volume":"14","author":"Z Li","year":"2023","unstructured":"Li, Z. et al. Immunological role and prognostic value of the SKA family in pan-cancer analysis. Front. Immunol. 14, 1012999 (2023).","journal-title":"Front. Immunol."},{"key":"914_CR93","doi-asserted-by":"crossref","first-page":"110554","DOI":"10.1016\/j.ygeno.2022.110554","volume":"115","author":"H Lan","year":"2023","unstructured":"Lan, H. et al. Pancancer analysis of SKA1 mutation and its association with the diagnosis and prognosis of human cancers. Genomics 115, 110554 (2023).","journal-title":"Genomics"},{"key":"914_CR94","volume":"159","author":"C Wang","year":"2022","unstructured":"Wang, C. et al. SKA3 is a prognostic biomarker and associated with immune infiltration in bladder cancer. Hereditas 159, 20 (2022).","journal-title":"Hereditas"},{"key":"914_CR95","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.3390\/cancers13184673","volume":"13","author":"C You","year":"2021","unstructured":"You, C., Piao, X. M., Kang, K., Kim, Y. J. & Kang, K. Integrative transcriptome profiling reveals SKA3 as a novel prognostic marker in non-muscle invasive bladder cancer. Cancers 13, 4673 (2021).","journal-title":"Cancers"},{"key":"914_CR96","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","volume":"26","author":"AS Dhillon","year":"2007","unstructured":"Dhillon, A. S., Hagan, S., Rath, O. & Kolch, W. MAP kinase signalling pathways in cancer. Oncogene 26, 3279\u20133290 (2007).","journal-title":"Oncogene"},{"key":"914_CR97","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/med.21288","volume":"34","author":"M Katoh","year":"2014","unstructured":"Katoh, M. & Nakagama, H. FGF receptors: cancer biology and therapeutics. Med. Res. Rev. 34, 280\u2013300 (2014).","journal-title":"Med. Res. Rev."},{"key":"914_CR98","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2005.05.1771","volume":"24","author":"S Hernandez","year":"2006","unstructured":"Hernandez, S. et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J. Clin. Oncol. 24, 3664\u20133671 (2006).","journal-title":"J. Clin. Oncol."},{"key":"914_CR99","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.eururo.2010.05.043","volume":"58","author":"BW van Rhijn","year":"2010","unstructured":"van Rhijn, B. W. et al. Molecular grade (FGFR3\/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur. Urol. 58, 433\u2013441 (2010).","journal-title":"Eur. Urol."},{"key":"914_CR100","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.eururo.2007.12.026","volume":"54","author":"M Burger","year":"2008","unstructured":"Burger, M. et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur. Urol. 54, 835\u2013843 (2008).","journal-title":"Eur. Urol."},{"key":"914_CR101","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.juro.2011.09.008","volume":"187","author":"BW van Rhijn","year":"2012","unstructured":"van Rhijn, B. W. et al. The FGFR3 mutation is related to favorable pT1 bladder cancer. J. Urol. 187, 310\u2013314 (2012).","journal-title":"J. Urol."},{"key":"914_CR102","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2020.07.002","volume":"78","author":"BWG van Rhijn","year":"2020","unstructured":"van Rhijn, B. W. G. et al. FGFR3 mutation status and FGFR3 expression in a large bladder cancer cohort treated by radical cystectomy: implications for anti-FGFR3 treatment?(\u2020). Eur. Urol. 78, 682\u2013687 (2020).","journal-title":"Eur. Urol."},{"key":"914_CR103","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1158\/0008-5472.CAN-03-2421","volume":"64","author":"BW van Rhijn","year":"2004","unstructured":"van Rhijn, B. W. et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res. 64, 1911\u20131914 (2004).","journal-title":"Cancer Res."},{"key":"914_CR104","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.3892\/ol.2017.6621","volume":"14","author":"HW Kang","year":"2017","unstructured":"Kang, H. W. et al. Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status. Oncol. Lett. 14, 3817\u20133824 (2017).","journal-title":"Oncol. Lett."},{"key":"914_CR105","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1158\/1078-0432.CCR-17-2719","volume":"24","author":"KEM van Kessel","year":"2018","unstructured":"van Kessel, K. E. M. et al. Molecular markers increase precision of the European Association of Urology non-muscle-invasive bladder cancer progression risk groups. Clin. Cancer Res. 24, 1586\u20131593 (2018).","journal-title":"Clin. Cancer Res."},{"key":"914_CR106","doi-asserted-by":"crossref","first-page":"102530","DOI":"10.1016\/j.ctrv.2023.102530","volume":"115","author":"CM Ascione","year":"2023","unstructured":"Ascione, C. M. et al. Role of FGFR3 in bladder cancer: treatment landscape and future challenges. Cancer Treat. Rev. 115, 102530 (2023).","journal-title":"Cancer Treat. Rev."},{"key":"914_CR107","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1470-2045(21)00660-4","volume":"23","author":"AO Siefker-Radtke","year":"2022","unstructured":"Siefker-Radtke, A. O. et al. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncol. 23, 248\u2013258 (2022).","journal-title":"Lancet Oncol."},{"key":"914_CR108","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.annonc.2023.09.3116","volume":"35","author":"JWF Catto","year":"2024","unstructured":"Catto, J. W. F. et al. Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer. Ann. Oncol. 35, 98\u2013106 (2024).","journal-title":"Ann. Oncol."},{"key":"914_CR109","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03914794 (2024)."},{"key":"914_CR110","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","volume":"26","author":"MM Moasser","year":"2007","unstructured":"Moasser, M. M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26, 6469\u20136487 (2007).","journal-title":"Oncogene"},{"key":"914_CR111","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11255-014-0866-z","volume":"47","author":"J Zhao","year":"2015","unstructured":"Zhao, J. et al. Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis. Int. Urol. Nephrol. 47, 87\u201394 (2015).","journal-title":"Int. Urol. Nephrol."},{"key":"914_CR112","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000453670","volume":"98","author":"J Breyer","year":"2017","unstructured":"Breyer, J. et al. ERBB2 expression as potential risk-stratification for early cystectomy in patients with pT1 bladder cancer and concomitant carcinoma in situ. Urol. Int. 98, 282\u2013289 (2017).","journal-title":"Urol. Int."},{"key":"914_CR113","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3346\/jkms.2015.30.8.1068","volume":"30","author":"SD Lim","year":"2015","unstructured":"Lim, S. D. et al. Clinical significance of substaging and HER2 expression in papillary nonmuscle invasive urothelial cancers of the urinary bladder. J. Korean Med. Sci. 30, 1068\u20131077 (2015).","journal-title":"J. Korean Med. Sci."},{"key":"914_CR114","doi-asserted-by":"publisher","unstructured":"Tan, X. et al. Prognostic significance of HER2 expression in patients with bacillus Calmette-Gu\u00e9rin-exposed non-muscle-invasive bladder cancer. Eur. Urol. Oncol. https:\/\/doi.org\/10.1016\/j.euo.2023.10.003 (2023).","DOI":"10.1016\/j.euo.2023.10.003"},{"key":"914_CR115","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.3390\/cancers14194570","volume":"14","author":"I Kocsm\u00e1r","year":"2022","unstructured":"Kocsm\u00e1r, I. et al. Addition of chromosome 17 polysomy and HER2 amplification status improves the accuracy of clinicopathological factor-based progression risk stratification and tumor grading of non-muscle-invasive bladder cancer. Cancers 14, 4570 (2022).","journal-title":"Cancers"},{"key":"914_CR116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/BLC-180196","volume":"5","author":"VS Koshkin","year":"2019","unstructured":"Koshkin, V. S., O\u2019Donnell, P., Yu, E. Y. & Grivas, P. Systematic review: targeting HER2 in bladder cancer. Bladder Cancer 5, 1\u201312 (2019).","journal-title":"Bladder Cancer"},{"key":"914_CR117","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/HCO.0000000000000637","volume":"34","author":"RS Copeland-Halperin","year":"2019","unstructured":"Copeland-Halperin, R. S., Liu, J. E. & Yu, A. F. Cardiotoxicity of HER2-targeted therapies. Curr. Opin. Cardiol. 34, 451\u2013458 (2019).","journal-title":"Curr. Opin. Cardiol."},{"key":"914_CR118","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain, S. M., Shastry, M. & Hamilton, E. Targeting HER2-positive breast cancer: advances and future directions. Nat. Rev. Drug. Discov. 22, 101\u2013126 (2023).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"914_CR119","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.annonc.2024.04.002","volume":"35","author":"S Peters","year":"2024","unstructured":"Peters, S. et al. Antibody-drug conjugates in lung and breast cancer: current evidence and future directions \u2014 a position statement from the ETOP IBCSG Partners Foundation. Ann. Oncol. 35, 607\u2013629 (2024).","journal-title":"Ann. Oncol."},{"key":"914_CR120","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","volume":"42","author":"X Sheng","year":"2024","unstructured":"Sheng, X. et al. Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials. J. Clin. Oncol. 42, 1391\u20131402 (2024).","journal-title":"J. Clin. Oncol."},{"key":"914_CR121","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","volume":"27","author":"X Sheng","year":"2021","unstructured":"Sheng, X. et al. Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma. Clin. Cancer Res. 27, 43\u201351 (2021).","journal-title":"Clin. Cancer Res."},{"key":"914_CR122","first-page":"438","volume":"40","author":"DG Matt","year":"2022","unstructured":"Matt, D. G. et al. Primary analysis from DS8201-A-U105: a phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC). J. Clin. Oncol. 40, 438\u2013438 (2022).","journal-title":"J. Clin. Oncol."},{"key":"914_CR123","doi-asserted-by":"crossref","first-page":"1326296","DOI":"10.3389\/fphar.2024.1326296","volume":"15","author":"CH Shih","year":"2024","unstructured":"Shih, C. H., Lin, Y. H., Luo, H. L. & Sung, W. W. Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma. Front. Pharmacol. 15, 1326296 (2024).","journal-title":"Front. Pharmacol."},{"key":"914_CR124","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.plipres.2013.09.002","volume":"52","author":"EJ Zerenturk","year":"2013","unstructured":"Zerenturk, E. J., Sharpe, L. J., Ikonen, E. & Brown, A. J. Desmosterol and DHCR24: unexpected new directions for a terminal step in cholesterol synthesis. Prog. Lipid Res. 52, 666\u2013680 (2013).","journal-title":"Prog. Lipid Res."},{"key":"914_CR125","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1194\/jlr.M043257","volume":"55","author":"W Luu","year":"2014","unstructured":"Luu, W. et al. Signaling regulates activity of DHCR24, the final enzyme in cholesterol synthesis. J. Lipid Res. 55, 410\u2013420 (2014).","journal-title":"J. Lipid Res."},{"key":"914_CR126","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1245\/s10434-014-3560-6","volume":"21","author":"GT Lee","year":"2014","unstructured":"Lee, G. T. et al. DHCR24 is an independent predictor of progression in patients with non-muscle-invasive urothelial carcinoma, and its functional role is involved in the aggressive properties of urothelial carcinoma cells. Ann. Surg. Oncol. 21, S538\u2013S545 (2014).","journal-title":"Ann. Surg. Oncol."},{"key":"914_CR127","volume":"97","author":"XP Liu","year":"2018","unstructured":"Liu, X. P. et al. DHCR24 predicts poor clinicopathological features of patients with bladder cancer: a STROBE-compliant study. Medicine 97, e11830 (2018).","journal-title":"Medicine"},{"key":"914_CR128","doi-asserted-by":"crossref","first-page":"20623","DOI":"10.1073\/pnas.1911992116","volume":"116","author":"A Korner","year":"2019","unstructured":"Korner, A. et al. Inhibition of \u039424-dehydrocholesterol reductase activates pro-resolving lipid mediator biosynthesis and inflammation resolution. Proc. Natl Acad. Sci. USA 116, 20623\u201320634 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"914_CR129","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1038\/s41416-020-01085-z","volume":"123","author":"J Wu","year":"2020","unstructured":"Wu, J. et al. Genkwadaphnin inhibits growth and invasion in hepatocellular carcinoma by blocking DHCR24-mediated cholesterol biosynthesis and lipid rafts formation. Br. J. Cancer 123, 1673\u20131685 (2020).","journal-title":"Br. J. Cancer"},{"key":"914_CR130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1023\/B:APPT.0000012119.83734.4e","volume":"9","author":"J Fang","year":"2004","unstructured":"Fang, J., Akaike, T. & Maeda, H. Antiapoptotic role of heme oxygenase (HO) and the potential of HO as a target in anticancer treatment. Apoptosis 9, 27\u201335 (2004).","journal-title":"Apoptosis"},{"key":"914_CR131","volume":"9","author":"WJ Kim","year":"2010","unstructured":"Kim, W. J. et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol. Cancer 9, 3 (2010).","journal-title":"Mol. Cancer"},{"key":"914_CR132","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.juro.2010.09.081","volume":"185","author":"M-S Yim","year":"2011","unstructured":"Yim, M.-S. et al. HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression. J. Urol. 185, 701\u2013705 (2011).","journal-title":"J. Urol."},{"key":"914_CR133","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jb\/mvaa027","volume":"168","author":"Y Peng","year":"2020","unstructured":"Peng, Y. et al. JUND-dependent up-regulation of HMOX1 is associated with cisplatin resistance in muscle-invasive bladder cancer. J. Biochem. 168, 73\u201382 (2020).","journal-title":"J. Biochem."},{"key":"914_CR134","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.trsl.2014.06.010","volume":"164","author":"Y Miyata","year":"2014","unstructured":"Miyata, Y., Kanda, S., Mitsunari, K., Asai, A. & Sakai, H. Heme oxygenase-1 expression is associated with tumor aggressiveness and outcomes in patients with bladder cancer: a correlation with smoking intensity. Transl. Res. 164, 468\u2013476 (2014).","journal-title":"Transl. Res."},{"key":"914_CR135","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3892\/ol.2016.5416","volume":"13","author":"T Matsuo","year":"2017","unstructured":"Matsuo, T. et al. Pathological significance and prognostic implications of heme oxygenase 1 expression in non-muscle-invasive bladder cancer: correlation with cell proliferation, angiogenesis, lymphangiogenesis and expression of VEGFs and COX-2. Oncol. Lett. 13, 275\u2013280 (2017).","journal-title":"Oncol. Lett."},{"key":"914_CR136","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1158\/1078-0432.CCR-04-2159","volume":"11","author":"PO Berberat","year":"2005","unstructured":"Berberat, P. O. et al. Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clin. Cancer Res. 11, 3790\u20133798 (2005).","journal-title":"Clin. Cancer Res."},{"key":"914_CR137","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1179\/1607845414Y.0000000212","volume":"20","author":"N Zhe","year":"2015","unstructured":"Zhe, N. et al. Heme oxygenase-1 plays a crucial role in chemoresistance in acute myeloid leukemia. Hematology 20, 384\u2013391 (2015).","journal-title":"Hematology"},{"key":"914_CR138","first-page":"23","volume":"22","author":"P Podkalicka","year":"2018","unstructured":"Podkalicka, P., Mucha, O., Jozkowicz, A., Dulak, J. & Loboda, A. Heme oxygenase inhibition in cancers: possible tools and targets. Contemp. Oncol. 22, 23\u201332 (2018).","journal-title":"Contemp. Oncol."},{"key":"914_CR139","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nrurol.2015.292","volume":"13","author":"M Alfano","year":"2016","unstructured":"Alfano, M. et al. The interplay of extracellular matrix and microbiome in urothelial bladder cancer. Nat. Rev. Urol. 13, 77\u201390 (2016).","journal-title":"Nat. Rev. Urol."},{"key":"914_CR140","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.eururo.2022.09.008","volume":"82","author":"T Strandgaard","year":"2022","unstructured":"Strandgaard, T. et al. Elevated T-cell exhaustion and urinary tumor DNA levels are associated with bacillus Calmette-Guerin failure in patients with non-muscle-invasive bladder cancer. Eur. Urol. 82, 646\u2013656 (2022).","journal-title":"Eur. Urol."},{"key":"914_CR141","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","volume":"109","author":"BA Inman","year":"2007","unstructured":"Inman, B. A. et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 109, 1499\u20131505 (2007).","journal-title":"Cancer"},{"key":"914_CR142","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41585-022-00608-y","volume":"19","author":"YC Lee","year":"2022","unstructured":"Lee, Y. C. et al. The dynamic roles of the bladder tumour microenvironment. Nat. Rev. Urol. 19, 515\u2013533 (2022).","journal-title":"Nat. Rev. Urol."},{"key":"914_CR143","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793\u2013800 (2002).","journal-title":"Nat. Med."},{"key":"914_CR144","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00262-006-0266-z","volume":"56","author":"J Nakanishi","year":"2007","unstructured":"Nakanishi, J. et al. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol. Immunother. 56, 1173\u20131182 (2007).","journal-title":"Cancer Immunol. Immunother."},{"key":"914_CR145","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.urolonc.2017.01.014","volume":"35","author":"C Le Goux","year":"2017","unstructured":"Le Goux, C. et al. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: a retrospective study. Urol. Oncol. 35, 257\u2013263 (2017).","journal-title":"Urol. Oncol."},{"key":"914_CR146","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.euo.2022.01.008","volume":"5","author":"A Taber","year":"2022","unstructured":"Taber, A. et al. Immune contexture and differentiation features predict outcome in bladder cancer. Eur. Urol. Oncol. 5, 203\u2013213 (2022).","journal-title":"Eur. Urol. Oncol."},{"key":"914_CR147","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00262-017-2093-9","volume":"67","author":"J Breyer","year":"2018","unstructured":"Breyer, J. et al. High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients. Cancer Immunol. Immunother. 67, 403\u2013412 (2018).","journal-title":"Cancer Immunol. Immunother."},{"key":"914_CR148","doi-asserted-by":"crossref","DOI":"10.1186\/s12894-018-0414-8","volume":"18","author":"T Kawahara","year":"2018","unstructured":"Kawahara, T. et al. PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer. BMC Urol. 18, 97 (2018).","journal-title":"BMC Urol."},{"key":"914_CR149","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.3892\/or.2015.3933","volume":"33","author":"Y Huang","year":"2015","unstructured":"Huang, Y. et al. The prognostic significance of PD-L1 in bladder cancer. Oncol. Rep. 33, 3075\u20133084 (2015).","journal-title":"Oncol. Rep."},{"key":"914_CR150","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/2090598X.2020.1791562","volume":"19","author":"\u0141 Nowak","year":"2021","unstructured":"Nowak, \u0141., Krajewski, W., Poterek, A., \u015aliwa, A. & Zdrojowy, R. The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette\u2013Gu\u00e9rin immunotherapy: current status. Arab. J. Urol. 19, 67\u201370 (2021).","journal-title":"Arab. J. Urol."},{"key":"914_CR151","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar, A. V. et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 22, 919\u2013930 (2021).","journal-title":"Lancet Oncol."},{"key":"914_CR152","doi-asserted-by":"crossref","first-page":"LBA442","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA442","volume":"41","author":"N Andrea","year":"2023","unstructured":"Andrea, N. et al. Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette\u2013Gu\u00e9rin (BCG): results from cohort B of the phase 2 KEYNOTE-057 trial. J. Clin. Oncol. 41, LBA442\u2013LBA442 (2023).","journal-title":"J. Clin. Oncol."},{"key":"914_CR153","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2023.08.004","volume":"84","author":"PC Black","year":"2023","unstructured":"Black, P. C. et al. Phase 2 trial of atezolizumab in bacillus Calmette-Gu\u00e9rin-unresponsive high-risk non-muscle-invasive bladder cancer: SWOG S1605. Eur. Urol. 84, 536\u2013544 (2023).","journal-title":"Eur. Urol."},{"key":"914_CR154","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.eururo.2023.01.017","volume":"83","author":"NM Hahn","year":"2023","unstructured":"Hahn, N. M. et al. A phase 1 trial of durvalumab in combination with bacillus Calmette-Guerin (BCG) or external beam radiation therapy in patients with BCG-unresponsive non-muscle-invasive bladder cancer: the Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER study. Eur. Urol. 83, 486\u2013494 (2023).","journal-title":"Eur. Urol."},{"key":"914_CR155","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1158\/1078-0432.CCR-23-0354","volume":"29","author":"R Li","year":"2023","unstructured":"Li, R. et al. A phase II study of durvalumab for bacillus Calmette-Guerin (BCG) unresponsive urothelial carcinoma in situ of the bladder. Clin. Cancer Res. 29, 3875\u20133881 (2023).","journal-title":"Clin. Cancer Res."},{"key":"914_CR156","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03528694 (2024)."},{"key":"914_CR157","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05943106 (2024)."},{"key":"914_CR158","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03892642 (2024)."},{"key":"914_CR159","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.3390\/ijms22062800","volume":"22","author":"FC de Jong","year":"2021","unstructured":"de Jong, F. C., Rutten, V. C., Zuiverloon, T. C. M. & Theodorescu, D. Improving anti-PD-1\/PD-L1 therapy for localized bladder cancer. Int. J. Mol. Sci. 22, 2800 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"914_CR160","doi-asserted-by":"crossref","first-page":"21944","DOI":"10.1002\/cam4.6768","volume":"12","author":"ZA Hannouneh","year":"2023","unstructured":"Hannouneh, Z. A. et al. Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer. Cancer Med. 12, 21944\u201321968 (2023).","journal-title":"Cancer Med."},{"key":"914_CR161","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002899","volume":"9","author":"A Hazini","year":"2021","unstructured":"Hazini, A., Fisher, K. & Seymour, L. Deregulation of HLA-I in cancer and its central importance for immunotherapy. J. Immunother. Cancer 9, e002899 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"914_CR162","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1158\/1078-0432.CCR-21-3501","volume":"28","author":"N Aptsiauri","year":"2022","unstructured":"Aptsiauri, N. & Garrido, F. The challenges of HLA class I loss in cancer immunotherapy: facts and hopes. Clin. Cancer Res. 28, 5021\u20135029 (2022).","journal-title":"Clin. Cancer Res."},{"key":"914_CR163","doi-asserted-by":"crossref","first-page":"7248","DOI":"10.3390\/ijms22147248","volume":"22","author":"H Gil-Julio","year":"2021","unstructured":"Gil-Julio, H. et al. Tumor escape phenotype in bladder cancer is associated with loss of HLA class I expression, T-cell exclusion and stromal changes. Int. J. Mol. Sci. 22, 7248 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"914_CR164","doi-asserted-by":"crossref","first-page":"757137","DOI":"10.3389\/fcell.2022.757137","volume":"10","author":"R Yi","year":"2022","unstructured":"Yi, R. et al. MHC-II signature correlates with anti-tumor immunity and predicts anti-PD-L1 response of bladder cancer. Front. Cell Dev. Biol. 10, 757137 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"914_CR165","doi-asserted-by":"crossref","first-page":"237.e21","DOI":"10.1016\/j.urolonc.2020.11.017","volume":"39","author":"XM Piao","year":"2021","unstructured":"Piao, X. M. et al. A prognostic immune predictor, HLA-DRA, plays diverse roles in non-muscle invasive and muscle invasive bladder cancer. Urol. Oncol. 39, 237.e21\u2013237.e29 (2021).","journal-title":"Urol. Oncol."},{"key":"914_CR166","doi-asserted-by":"crossref","first-page":"eabn4118","DOI":"10.1126\/scitranslmed.abn4118","volume":"15","author":"FC de Jong","year":"2023","unstructured":"de Jong, F. C. et al. Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Guerin. Sci. Transl. Med. 15, eabn4118 (2023).","journal-title":"Sci. Transl. Med."},{"key":"914_CR167","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021108647","volume":"40","author":"S Brabletz","year":"2021","unstructured":"Brabletz, S., Schuhwerk, H., Brabletz, T. & Stemmler, M. P. Dynamic EMT: a multi-tool for tumor progression. EMBO J. 40, e108647 (2021).","journal-title":"EMBO J."},{"key":"914_CR168","doi-asserted-by":"crossref","first-page":"151220","DOI":"10.1016\/j.ejcb.2022.151220","volume":"101","author":"S Banerjee","year":"2022","unstructured":"Banerjee, S. et al. Multiple roles for basement membrane proteins in cancer progression and EMT. Eur. J. Cell Biol. 101, 151220 (2022).","journal-title":"Eur. J. Cell Biol."},{"key":"914_CR169","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.2147\/OTT.S194568","volume":"12","author":"H Zhu","year":"2019","unstructured":"Zhu, H., Chen, H., Wang, J., Zhou, L. & Liu, S. Collagen stiffness promoted non-muscle-invasive bladder cancer progression to muscle-invasive bladder cancer. Onco Targets Ther. 12, 3441\u20133457 (2019).","journal-title":"Onco Targets Ther."},{"key":"914_CR170","doi-asserted-by":"crossref","first-page":"82609","DOI":"10.18632\/oncotarget.12089","volume":"7","author":"M Brooks","year":"2016","unstructured":"Brooks, M. et al. Positive association of collagen type I with non-muscle invasive bladder cancer progression. Oncotarget 7, 82609\u201382619 (2016).","journal-title":"Oncotarget"},{"key":"914_CR171","doi-asserted-by":"crossref","first-page":"78918","DOI":"10.18632\/oncotarget.12912","volume":"7","author":"MC Tsai","year":"2016","unstructured":"Tsai, M. C. et al. DDR2 overexpression in urothelial carcinoma indicates an unfavorable prognosis: a large cohort study. Oncotarget 7, 78918\u201378931 (2016).","journal-title":"Oncotarget"},{"key":"914_CR172","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.2023.41.6_suppl.570","volume":"41","author":"JB Cyrenne","year":"2023","unstructured":"Cyrenne, J. B. et al. Comprehensive gene sequencing to identify progression predictors to muscle-invasive bladder cancer. J. Clin. Oncol. 41, 570\u2013570 (2023).","journal-title":"J. Clin. Oncol."},{"key":"914_CR173","volume":"11","author":"Z Chen","year":"2020","unstructured":"Chen, Z. et al. Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma. Nat. Commun. 11, 5077 (2020).","journal-title":"Nat. Commun."},{"key":"914_CR174","volume":"9","author":"L Wang","year":"2018","unstructured":"Wang, L. et al. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nat. Commun. 9, 3503 (2018).","journal-title":"Nat. Commun."},{"key":"914_CR175","doi-asserted-by":"crossref","first-page":"eaav2437","DOI":"10.1126\/sciadv.aav2437","volume":"5","author":"MM Tu","year":"2019","unstructured":"Tu, M. M. et al. Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy. Sci. Adv. 5, eaav2437 (2019).","journal-title":"Sci. Adv."},{"key":"914_CR176","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/jnci\/djac140","volume":"114","author":"S You","year":"2022","unstructured":"You, S. et al. Discoidin domain receptor-driven gene signatures as markers of patient response to anti-PD-L1 immune checkpoint therapy. J. Natl Cancer Inst. 114, 1380\u20131391 (2022).","journal-title":"J. Natl Cancer Inst."},{"key":"914_CR177","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"key":"914_CR178","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1158\/1078-0432.CCR-18-3147","volume":"25","author":"AH Nassar","year":"2019","unstructured":"Nassar, A. H. et al. Mutational analysis of 472 urothelial carcinoma across grades and anatomic sites. Clin. Cancer Res. 25, 2458\u20132470 (2019).","journal-title":"Clin. Cancer Res."},{"key":"914_CR179","doi-asserted-by":"crossref","first-page":"5698","DOI":"10.1093\/nar\/gkae233","volume":"52","author":"A Bakr","year":"2024","unstructured":"Bakr, A. et al. ARID1A regulates DNA repair through chromatin organization and its deficiency triggers DNA damage-mediated anti-tumor immune response. Nucleic Acids Res. 52, 5698\u20135719 (2024).","journal-title":"Nucleic Acids Res."},{"key":"914_CR180","volume":"8","author":"C Balbas-Martinez","year":"2013","unstructured":"Balbas-Martinez, C. et al. ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors. PLoS ONE 8, e62483 (2013).","journal-title":"PLoS ONE"},{"key":"914_CR181","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2023.07.014","volume":"85","author":"T Strandgaard","year":"2023","unstructured":"Strandgaard, T. et al. Field cancerization is associated with tumor development, T-cell exhaustion, and clinical outcomes in bladder cancer. Eur. Urol. 85, 82\u201392 (2023).","journal-title":"Eur. Urol."},{"key":"914_CR182","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1126\/science.aba8347","volume":"370","author":"ARJ Lawson","year":"2020","unstructured":"Lawson, A. R. J. et al. Extensive heterogeneity in somatic mutation and selection in the human bladder. Science 370, 75\u201382 (2020).","journal-title":"Science"},{"key":"914_CR183","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3233\/BLC-200289","volume":"6","author":"DA Bastos","year":"2020","unstructured":"Bastos, D. A. et al. Genomic biomarkers and underlying mechanism of benefit from BCG immunotherapy in non-muscle invasive bladder cancer. Bladder Cancer 6, 171\u2013186 (2020).","journal-title":"Bladder Cancer"},{"key":"914_CR184","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12929-022-00856-5","volume":"29","author":"J Mandal","year":"2022","unstructured":"Mandal, J., Mandal, P., Wang, T.-L. & Shih, I.-M. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response. J. Biomed. Sci. 29, 71 (2022).","journal-title":"J. Biomed. Sci."},{"key":"914_CR185","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrm3822","volume":"15","author":"JA Marteijn","year":"2014","unstructured":"Marteijn, J. A., Lans, H., Vermeulen, W. & Hoeijmakers, J. H. Understanding nucleotide excision repair and its roles in cancer and ageing. Nat. Rev. Mol. Cell Biol. 15, 465\u2013481 (2014).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"914_CR186","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/ng.3557","volume":"48","author":"J Kim","year":"2016","unstructured":"Kim, J. et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat. Genet. 48, 600\u2013606 (2016).","journal-title":"Nat. Genet."},{"key":"914_CR187","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1158\/1078-0432.CCR-18-1001","volume":"25","author":"Q Li","year":"2019","unstructured":"Li, Q. et al. ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer. Clin. Cancer Res. 25, 977\u2013988 (2019).","journal-title":"Clin. Cancer Res."},{"key":"914_CR188","doi-asserted-by":"crossref","first-page":"831146","DOI":"10.3389\/fgene.2022.831146","volume":"13","author":"F Wang","year":"2022","unstructured":"Wang, F., Dong, X., Yang, F. & Xing, N. Comparative analysis of differentially mutated genes in non-muscle and muscle-invasive bladder cancer in the Chinese population by whole exome sequencing. Front. Genet. 13, 831146 (2022).","journal-title":"Front. Genet."},{"key":"914_CR189","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41585-023-00773-8","volume":"20","author":"M Maas","year":"2023","unstructured":"Maas, M., Todenh\u00f6fer, T. & Black, P. C. Urine biomarkers in bladder cancer \u2014 current status and future perspectives. Nat. Rev. Urol. 20, 597\u2013614 (2023).","journal-title":"Nat. Rev. Urol."},{"key":"914_CR190","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.3892\/ol.2017.6408","volume":"14","author":"HW Kang","year":"2017","unstructured":"Kang, H. W. et al. Long-term validation of a molecular progression-associated gene classifier for prediction of muscle invasion in primary non-muscle-invasive bladder cancer. Oncol. Lett. 14, 2468\u20132474 (2017).","journal-title":"Oncol. Lett."},{"key":"914_CR191","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.clgc.2018.02.001","volume":"16","author":"HW Kang","year":"2018","unstructured":"Kang, H. W. et al. Molecular progression risk score for prediction of muscle invasion in primary T1 high-grade bladder cancer. Clin. Genitourin. Cancer 16, 274\u2013280 (2018).","journal-title":"Clin. Genitourin. Cancer"},{"key":"914_CR192","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrc3458","volume":"13","author":"KF Harvey","year":"2013","unstructured":"Harvey, K. F., Zhang, X. & Thomas, D. M. The Hippo pathway and human cancer. Nat. Rev. Cancer 13, 246\u2013257 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"914_CR193","doi-asserted-by":"crossref","first-page":"104092","DOI":"10.1016\/j.ebiom.2022.104092","volume":"81","author":"S-W Baek","year":"2022","unstructured":"Baek, S.-W. et al. YAP1 activation is associated with the progression and response to immunotherapy of non-muscle invasive bladder cancer. eBioMedicine 81, 104092 (2022).","journal-title":"eBioMedicine"},{"key":"914_CR194","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/bjc.2012.412","volume":"107","author":"L Dyrskjot","year":"2012","unstructured":"Dyrskjot, L. et al. Analysis of molecular intra-patient variation and delineation of a prognostic 12-gene signature in non-muscle invasive bladder cancer; technology transfer from microarrays to PCR. Br. J. Cancer 107, 1392\u20131398 (2012).","journal-title":"Br. J. Cancer"},{"key":"914_CR195","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.eururo.2017.05.040","volume":"72","author":"L Dyrskjot","year":"2017","unstructured":"Dyrskjot, L. et al. Prognostic impact of a 12-gene progression score in non-muscle-invasive bladder cancer: a prospective multicentre validation study. Eur. Urol. 72, 461\u2013469 (2017).","journal-title":"Eur. Urol."},{"key":"914_CR196","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","volume":"72","author":"R Seiler","year":"2017","unstructured":"Seiler, R. et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur. Urol. 72, 544\u2013554 (2017).","journal-title":"Eur. Urol."},{"key":"914_CR197","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540\u2013556 e25 (2017).","journal-title":"Cell"},{"key":"914_CR198","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","volume":"18","author":"G Sjodahl","year":"2012","unstructured":"Sjodahl, G. et al. A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res. 18, 3377\u20133386 (2012).","journal-title":"Clin. Cancer Res."},{"key":"914_CR199","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-22126-x","volume":"8","author":"NA Marzouka","year":"2018","unstructured":"Marzouka, N. A. et al. A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort. Sci. Rep. 8, 3737 (2018).","journal-title":"Sci. Rep."},{"key":"914_CR200","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4886","volume":"242","author":"G Sjodahl","year":"2017","unstructured":"Sjodahl, G., Eriksson, P., Liedberg, F. & Hoglund, M. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification. J. Pathol. 242, 113\u2013125 (2017).","journal-title":"J. Pathol."},{"key":"914_CR201","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jmoldx.2022.05.006","volume":"24","author":"NA Marzouka","year":"2022","unstructured":"Marzouka, N. A. et al. The Lund molecular taxonomy applied to non-muscle-invasive urothelial carcinoma. J. Mol. Diagn. 24, 992\u20131008 (2022).","journal-title":"J. Mol. Diagn."},{"key":"914_CR202","doi-asserted-by":"publisher","unstructured":"Aramend\u00eda Cotillas, E. et al. A versatile and upgraded version of the LundTax classification algorithm applied to independent cohorts. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2023.12.15.571519v1 (2023).","DOI":"10.1101\/2023.12.15.571519v1"},{"key":"914_CR203","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","volume":"30","author":"J Hedegaard","year":"2016","unstructured":"Hedegaard, J. et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell 30, 27\u201342 (2016).","journal-title":"Cancer Cell"},{"key":"914_CR204","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-022-01056-4","volume":"14","author":"A Goel","year":"2022","unstructured":"Goel, A. et al. Combined exome and transcriptome sequencing of non-muscle-invasive bladder cancer: associations between genomic changes, expression subtypes, and clinical outcomes. Genome Med. 14, 59 (2022).","journal-title":"Genome Med."},{"key":"914_CR205","unstructured":"Erasmus Urology Research. IMPASSE-trial: improved patient stratification by molecular subtyping of high-risk non-muscle invasive bladder cancer and identification of novel treatments by ex vivo medium-throughput drug screening. Erasmus Urology Research https:\/\/www.erasmusurologyresearch.nl\/impasse-trial\/ (2024)."},{"key":"914_CR206","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41585-020-0304-1","volume":"17","author":"JJ Meeks","year":"2020","unstructured":"Meeks, J. J. et al. Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nat. Rev. Urol. 17, 259\u2013270 (2020).","journal-title":"Nat. Rev. Urol."},{"key":"914_CR207","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.euros.2023.03.006","volume":"51","author":"SV Lindskrog","year":"2023","unstructured":"Lindskrog, S. V. et al. Single-nucleus and spatially resolved intratumor subtype heterogeneity in bladder cancer. Eur. Urol. Open Sci. 51, 78\u201388 (2023).","journal-title":"Eur. Urol. Open Sci."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00914-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00914-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00914-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T08:05:10Z","timestamp":1738742710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00914-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,2]]},"references-count":207,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["914"],"URL":"https:\/\/doi.org\/10.1038\/s41585-024-00914-7","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,2]]},"assertion":[{"value":"21 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.M. has a research collaboration with HUB Organoids, Gilead and Viiv. J.L.B. receives consultancy fees (all paid to Erasmus MC) from Janssen, BMS, AstraZeneca, Merck AG\/Pfizer, MSD and Bayer. He\u00a0also has research collaborations with Merck AG\/Pfizer, MSD, Janssen, and\u00a0VitroScan and has done\u00a0book writing for Astellas. T.C.M.Z. has research collaborations with Vitroscan, HUB Organoids and Valar Labs. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}